Sanofi — Earnings Release 2011

Mar 29, 2012

Genzyme key products: consolidated sales by geographic region ‐ 2011

Q1 2011 net sales * (€ million)	Western Europe	United States	Emerging Markets	Rest of the World	TOTAL
Cerezyme®	55	37	34	13		139
Myozyme® /Lumizyme®	54	21	12	7		94
Fabrazyme®	8	13	4	5		30
Other Rare Diseases products **	22	28	15	16		81
Total Rare Diseases	139	99	65	41		344
Renagel® /Renvela®	33	84	11	3		131
Synvisc® /Synvisc One®	6	53	3	8		70

Q2 2011 consolidated net sales (€ million)	Western Europe	United States	Emerging Markets	Rest of the World	TOTAL
Cerezyme®	61	42	48	15	166
Myozyme® /Lumizyme®	58	25	10	6	99
Fabrazyme®	7	13	4	6	30
Other Rare Diseases products **	18	29	13	19	79
Total Rare Diseases	144	109	75	46	374
Renagel® /Renvela®	35	80	12	10	137
Synvisc® /Synvisc One®	6	69	5	9	89

Q3 2011 consolidated net sales (€ million)	Western Europe	United States	Emerging Markets	Rest of the World	TOTAL
Cerezyme®	44	40	43	14	141
Myozyme® /Lumizyme®	57	26	12	6	101
Fabrazyme®	7	10	5	10	32
Other Rare Diseases products **	18	30	18	20	86
Total Rare Diseases	126	106	78	50	360
Renagel® /Renvela®	31	86	12	6	135
Synvisc® /Synvisc One®	5	66	4	5	80

Q4 2011 consolidated net sales (€ million)	Western Europe	United States	Emerging Markets	Rest of the World	TOTAL
Cerezyme®	51	25	44	13	133
Myozyme® /Lumizyme®	61	29	11	7	108
Fabrazyme®	9	25	5	8	47
Other Rare Diseases products **	22	34	21	23	100
Total Rare Diseases	143	113	81	51	388
Renagel® /Renvela®	32	99	6	6	143
Synvisc® /Synvisc One®	5	76	4	2	87

2011 net sales * (€ million)	Western Europe	United States	Emerging Markets	Rest of the World	TOTAL
Cerezyme®	211	144	169	55	579
Myozyme® /Lumizyme®	230	101	45	26	402
Fabrazyme®	31	61	18	29	139
Other Rare Diseases products **	80	121	67	78	346
Total Rare Diseases	552	427	299	188	1,466
Renagel® /Renvela®	131	349	41	25	546
Synvisc® /Synvisc One®	22	264	16	24	326

TOTAL
	166
	99
	30
	79
	374
	137
	89

TOTAL
	141
	101
	32
	86
	360
	135
	80

TOTAL
	133
	108
	47
	100
	388
	143
	87

TOTAL
	579
	402
	139
	346
	1,466
	546
	326

* Q1 2011 sales were not consolidated by Sanofi

** Other Rare Diseases products include Cholestagel, Welchol, Aldurazyme, Elaprase, Thyrogen

From 2012, Sanofi financial press releases will include Genzyme sales, consisting of Rare Diseases products (Cerezyme®, Myozyme®/Lumizyme®, Fabrazyme® and Other Rare Diseases products) and Multiple Sclerosis products.

Sanofi will continue to provide sales of Renagel®/Renvela® and Synvisc®/Synvisc One® which are now part of Sanofi pharmaceuticals.